Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
ACG Case Rep J ; 8(11): e00698, 2021 Nov.
Article in English | MEDLINE | ID: mdl-34820467

ABSTRACT

Primary effusion lymphoma (PEL) is a rare AIDS-associated non-Hodgkin lymphoma, growing in the serous body cavities as a lymphomatous effusion. The endoscopic features of PEL can mimic Kaposi sarcoma (KS). We present a case where PEL presented as small intestinal masses which had a similar macroscopic appearance to KS. Endoscopic evaluation was used with biopsies which confirmed the diagnosis of PEL. PEL is a differential of gastrointestinal KS. Accurate diagnosis is crucial for prognostication in these patients. Our case emphasizes that PEL presenting as intestinal tumors can mimic KS macroscopically. Although treatment for PEL and KS includes standard chemotherapy with concurrent antiretroviral therapy, early detection of PEL can improve overall survival in these patients.

2.
Melanoma Res ; 27(3): 271-273, 2017 06.
Article in English | MEDLINE | ID: mdl-28146044

ABSTRACT

Drug reaction with eosinophilia and systemic symptom syndrome is a potentially fatal drug reaction that must be recognized quickly. Ipilimumab and nivolumab are both important agents in the treatment of melanoma and continue to be studied in other malignancies. We believe the mainstay of therapy for immunotherapy-induced drug reaction with eosinophilia and systemic symptom syndrome is early recognition, discontinuation of the inciting agent, supportive care, and treatment with high dose corticosteroids with appropriate tapers that may reduce the length of internal organ injury in cases with liver or kidney involvement.


Subject(s)
Antibodies, Monoclonal/adverse effects , Drug Hypersensitivity Syndrome/etiology , Eosinophilia/pathology , Immunotherapy/adverse effects , Ipilimumab/adverse effects , Melanoma/drug therapy , Adrenal Cortex Hormones/therapeutic use , Antineoplastic Agents, Immunological/adverse effects , Cell Cycle Checkpoints/drug effects , Drug Hypersensitivity Syndrome/drug therapy , Drug Hypersensitivity Syndrome/pathology , Eosinophilia/chemically induced , Eosinophilia/drug therapy , Humans , Male , Melanoma/pathology , Middle Aged , Nivolumab , Prognosis
SELECTION OF CITATIONS
SEARCH DETAIL